BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 27726232)

  • 1. Li-Fraumeni syndrome presenting as mucosal melanoma: Case report and treatment considerations.
    Klein JD; Kupferman ME
    Head Neck; 2017 Feb; 39(2):E20-E22. PubMed ID: 27726232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes.
    Ruijs MW; Verhoef S; Rookus MA; Pruntel R; van der Hout AH; Hogervorst FB; Kluijt I; Sijmons RH; Aalfs CM; Wagner A; Ausems MG; Hoogerbrugge N; van Asperen CJ; Gomez Garcia EB; Meijers-Heijboer H; Ten Kate LP; Menko FH; van 't Veer LJ
    J Med Genet; 2010 Jun; 47(6):421-8. PubMed ID: 20522432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequency of radiation-induced malignancies post-adjuvant radiotherapy for breast cancer in patients with Li-Fraumeni syndrome.
    Le AN; Harton J; Desai H; Powers J; Zelley K; Bradbury AR; Nathanson KL; Shah PD; Doucette A; Freedman GM; Gabriel P; Domchek SM; MacFarland SP; Maxwell KN
    Breast Cancer Res Treat; 2020 May; 181(1):181-188. PubMed ID: 32246378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Malignant triton tumor in a patient with Li-Fraumeni syndrome and a novel TP53 mutation.
    Chao MM; Levine JE; Ruiz RE; Kohlmann WK; Bower MA; Petty EM; Mody RJ
    Pediatr Blood Cancer; 2007 Dec; 49(7):1000-4. PubMed ID: 16333835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TP53 germline mutation may affect response to anticancer treatments: analysis of an intensively treated Li-Fraumeni family.
    Kappel S; Janschek E; Wolf B; Rudas M; Teleky B; Jakesz R; Kandioler D
    Breast Cancer Res Treat; 2015 Jun; 151(3):671-8. PubMed ID: 25981898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TP53 and CDKN1A mutation analysis in families with Li-Fraumeni and Li-Fraumeni like syndromes.
    Andrade RC; Dos Santos AC; de Aguirre Neto JC; Nevado J; Lapunzina P; Vargas FR
    Fam Cancer; 2017 Apr; 16(2):243-248. PubMed ID: 27714481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Li-Fraumeni syndrome: a paradigm for the understanding of hereditary cancer predisposition.
    Valdez JM; Nichols KE; Kesserwan C
    Br J Haematol; 2017 Feb; 176(4):539-552. PubMed ID: 27984644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A case of late-onset Li-Fraumeni-like syndrome with unilateral breast cancer.
    Cho Y; Kim J; Kim Y; Jeong J; Lee KA
    Ann Lab Med; 2013 May; 33(3):212-6. PubMed ID: 23667851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Germ line BAX alterations are infrequent in Li-Fraumeni syndrome.
    Barlow JW; Mous M; Wiley JC; Varley JM; Lozano G; Strong LC; Malkin D
    Cancer Epidemiol Biomarkers Prev; 2004 Aug; 13(8):1403-6. PubMed ID: 15298965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Super-Transactivation TP53 Variant in the Germline of a Family with Li-Fraumeni Syndrome.
    Id Said B; Kim H; Tran J; Novokmet A; Malkin D
    Hum Mutat; 2016 Sep; 37(9):889-92. PubMed ID: 27297285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic counseling can influence the course of a suspected familial cancer syndrome patient: from a case of Li-Fraumeni like syndrome with a germline mutation in the TP53 gene.
    Hwang SM; Lee ES; Shin SH; Kong SY
    Korean J Lab Med; 2008 Dec; 28(6):493-7. PubMed ID: 19127115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Li-Fraumeni and Li-Fraumeni-like syndrome among children diagnosed with pediatric cancer in Southern Brazil.
    Giacomazzi J; Selistre SG; Rossi C; Alemar B; Santos-Silva P; Pereira FS; Netto CB; Cossio SL; Roth DE; Brunetto AL; Zagonel-Oliveira M; Martel-Planche G; Goldim JR; Hainaut P; Camey SA; Ashton-Prolla P
    Cancer; 2013 Dec; 119(24):4341-9. PubMed ID: 24122735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The first two confirmed sub-Saharan African families with germline TP53 mutations causing Li-Fraumeni syndrome.
    Macaulay S; Goodyear QC; Kruger M; Chen W; Essop F; Krause A
    Fam Cancer; 2018 Oct; 17(4):607-613. PubMed ID: 29392648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Li-Fraumeni syndrome in Tunisian carriers with different and rare tumor phenotype: genotype-phenotype correlation.
    Sassi H; Meddeb R; Cherif MA; Nasr C; Riahi A; Hannachi S; Belguith N; M'rad R
    BMC Med Genomics; 2022 Mar; 15(1):44. PubMed ID: 35246108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Report of Multidisciplinary Treatment for Sisters with Li-Fraumeni Syndrome].
    Suzuki O; Amano K; Chika N; Yamano T; Eguchi H; Nakashima H; Ooya S; Okazaki Y; Mochiki E; Takahashi T; Ishida H
    Gan To Kagaku Ryoho; 2022 Dec; 49(13):1947-1949. PubMed ID: 36733053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation between choroid plexus carcinoma and Li-Fraumeni syndrome: implications of TP53 mutations and management strategies-a case-based narrative review.
    Mallik D; Gopal S; Scalia G; Umana G; Rajeswarie RT; Chaurasia B
    Childs Nerv Syst; 2024 Jun; 40(6):1699-1705. PubMed ID: 38316675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Germline TP53 mutations and the changing landscape of Li-Fraumeni syndrome.
    Kamihara J; Rana HQ; Garber JE
    Hum Mutat; 2014 Jun; 35(6):654-62. PubMed ID: 24706533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Case Report : Li-Fraumeni Syndrome with Central Nervous System Tumors in Two Siblings.
    Fang Z; Su Y; Sun H; Ge M; Qi Z; Hao C; Qian S; Ma X
    BMC Pediatr; 2021 Dec; 21(1):588. PubMed ID: 34961499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of germline or somatic TP53 missense mutation with oncogene amplification in tumors developed in patients with Li-Fraumeni or Li-Fraumeni-like syndrome.
    Sugawara W; Arai Y; Kasai F; Fujiwara Y; Haruta M; Hosaka R; Nishida K; Kurosumi M; Kobayashi Y; Akagi K; Kaneko Y
    Genes Chromosomes Cancer; 2011 Jul; 50(7):535-45. PubMed ID: 21484931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of TP53 Pro72Arg and MDM2 SNP285-SNP309 polymorphisms in an Italian cohort of LFS suggestive patients lacking identifiable TP53 germline mutations.
    Ponti F; Corsini S; Gnoli M; Pedrini E; Mordenti M; Sangiorgi L
    Fam Cancer; 2016 Oct; 15(4):635-43. PubMed ID: 26956143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.